Literature DB >> 17338926

Pathology of pulmonary hypertension.

Rubin M Tuder1, John C Marecki, Amy Richter, Iwona Fijalkowska, Sonia Flores.   

Abstract

The secondary role of pathology in the present clinical management of pulmonary hypertension (PH) reflects to some extent the limitations of the current understanding of the disease. Ample room exists for the diagnostic translation of the pathobiologic studies, with the goal of improving the diagnostic and prognostic power of the pathologic assessment of pulmonary vascular remodeling. This article seeks to show the complementarities of the pathology and pathobiology of PH.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17338926      PMCID： PMC1924722          DOI： 10.1016/j.ccm.2006.11.010

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN： 0272-5231            Impact factor:   2.878


  116 in total

1.  Prostacyclin analogs as the brakes for pulmonary artery smooth muscle cell proliferation: is it sufficient to treat severe pulmonary hypertension?

Authors:  Rubin M Tuder; Ari L Zaiman
Journal:  Am J Respir Cell Mol Biol       Date:  2002-02       Impact factor: 6.914

Review 2.  The pathobiology of pulmonary hypertension. Endothelium.

Authors:  R M Tuder; C D Cool; M Yeager; L Taraseviciene-Stewart; T M Bull; N F Voelkel
Journal:  Clin Chest Med       Date:  2001-09       Impact factor: 2.878

3.  Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension.

Authors:  A I Campbell; Y Zhao; R Sandhu; D J Stewart
Journal:  Circulation       Date:  2001-10-30       Impact factor: 29.690

4.  "Natural history" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease.

Authors:  R Kessler; M Faller; E Weitzenblum; A Chaouat; A Aykut; A Ducoloné; M Ehrhart; M Oswald-Mammosser
Journal:  Am J Respir Crit Care Med       Date:  2001-07-15       Impact factor: 21.405

Review 5.  Severe pulmonary hypertension after the discovery of the familial primary pulmonary hypertension gene.

Authors:  R M Tuder; M E Yeager; M Geraci; H A Golpon; N F Voelkel
Journal:  Eur Respir J       Date:  2001-06       Impact factor: 16.671

6.  Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins.

Authors:  N W Morrell; X Yang; P D Upton; K B Jourdan; N Morgan; K K Sheares; R C Trembath
Journal:  Circulation       Date:  2001-08-14       Impact factor: 29.690

7.  Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis.

Authors:  R M Tuder; M Chacon; L Alger; J Wang; L Taraseviciene-Stewart; Y Kasahara; C D Cool; A E Bishop; M Geraci; G L Semenza; M Yacoub; J M Polak; N F Voelkel
Journal:  J Pathol       Date:  2001-10       Impact factor: 7.996

8.  Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy.

Authors:  R Speich; R Jenni; M Opravil; R Jaccard
Journal:  Swiss Med Wkly       Date:  2001-12-01       Impact factor: 2.193

9.  Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension.

Authors:  S Eddahibi; M Humbert; E Fadel; B Raffestin; M Darmon; F Capron; G Simonneau; P Dartevelle; M Hamon; S Adnot
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 10.  Genomic approaches to research in pulmonary hypertension.

Authors:  M W Geraci; B Gao; Y Hoshikawa; M E Yeager; R M Tuder; N F Voelkel
Journal:  Respir Res       Date:  2001-05-01
View more
  143 in total

1.  Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension.

Authors:  Rubin M Tuder; Laura A Davis; Brian B Graham
Journal:  Am J Respir Crit Care Med       Date:  2011-11-10       Impact factor: 21.405

2.  Modern age pathology of pulmonary arterial hypertension.

Authors:  Elvira Stacher; Brian B Graham; James M Hunt; Aneta Gandjeva; Steve D Groshong; Vallerie V McLaughlin; Marsha Jessup; William E Grizzle; Michaela A Aldred; Carlyne D Cool; Rubin M Tuder
Journal:  Am J Respir Crit Care Med       Date:  2012-06-07       Impact factor: 21.405

3.  Transforming growth factor-β inhibition attenuates pulmonary arterial hypertension in rats.

Authors:  Aikaterini J Megalou; Chryssoula Glava; Dimitrios L Oikonomidis; Agapi Vilaeti; Maria G Agelaki; Giannis G Baltogiannis; Apostolos Papalois; Antonios P Vlahos; Theofilos M Kolettis
Journal:  Int J Clin Exp Med       Date:  2010-10-23

4.  Vascular Dysfunction in Pneumocystis-Associated Pulmonary Hypertension Is Related to Endothelin Response and Adrenomedullin Concentration.

Authors:  Dan W Siemsen; Erin Dobrinen; Soo Han; Kari Chiocchi; Nicole Meissner; Steve D Swain
Journal:  Am J Pathol       Date:  2015-12-11       Impact factor: 4.307

5.  Cardiac and vascular atrogin-1 mRNA expression is not associated with dexamethasone efficacy in the monocrotaline model of pulmonary hypertension.

Authors:  Michael L Paffett; Meghan M Channell; Jay S Naik; Selita N Lucas; Matthew J Campen
Journal:  Cardiovasc Toxicol       Date:  2012-09       Impact factor: 3.231

6.  Computational Simulation of the Pulmonary Arteries and its Role in the Study of Pediatric Pulmonary Hypertension.

Authors:  Kendall S Hunter; Jeffrey A Feinstein; D Dunbar Ivy; Robin Shandas
Journal:  Prog Pediatr Cardiol       Date:  2010-12-01

7.  Varicella zoster virus vasculopathy: analysis of virus-infected arteries.

Authors:  M A Nagel; I Traktinskiy; Y Azarkh; B Kleinschmidt-DeMasters; T Hedley-Whyte; A Russman; E M VanEgmond; K Stenmark; M Frid; R Mahalingam; M Wellish; A Choe; R Cordery-Cotter; R J Cohrs; D Gilden
Journal:  Neurology       Date:  2011-07-13       Impact factor: 9.910

8.  Delineating the angiogenic gene expression profile before pulmonary vascular remodeling in a lamb model of congenital heart disease.

Authors:  Jing Tian; Sohrab Fratz; Yali Hou; Qing Lu; Agnes Görlach; John Hess; Christian Schreiber; Sanjeev A Datar; Peter Oishi; John Nechtman; Robert Podolsky; Jin-Xiong She; Jeffrey R Fineman; Stephen M Black
Journal:  Physiol Genomics       Date:  2010-10-26       Impact factor: 3.107

Review 9.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

10.  Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension.

Authors:  Revathi Rajkumar; Kazuhisa Konishi; Thomas J Richards; David C Ishizawar; Andrew C Wiechert; Naftali Kaminski; Ferhaan Ahmad
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-01-15       Impact factor: 4.733
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.